Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of
progressive multiple sclerosis. Half of the patients will receive NAC, while the other half
will receive a placebo.